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Got Shigella? A Community Responds
 Fran Hall, RN, BSN
Pee Dee District Director, Disease 
Surveillance & Response
Stacy  Holley, RN, BSN
Disease Surveillance & Response Nurse
In early August of 2004, a local school nurse in Marlboro County 
notified the District DHEC Epi Nurse that about half the children in 
a pre-k class had a diarrhea illness, which seemed to be spreading. 
This was a large school of approximately 800 students in grades 
pre-k to eight and was very close to the North Carolina border. An 
epidemiological investigation was initiated immediately, which 
soon confirmed an outbreak of Shigella.
 The main objectives of the investigation were to stop further 
transmission and to identify the causative organism. A Physician's 
Advisory was prepared and faxed to all healthcare providers 
to alert them about the increased number of cases of Shigella. 
Included in the advisory was information on transmission modes, 
symptoms, treatment methods, and ways to report illnesses 
to DHEC. Physicians were also directed to the DHEC web site 
for accessing the 2004-2005 School Exclusion Guidelines to 
assist them in determining when a child could return to school. 
Communication with local physicians and emergency rooms in the 
area, including those across the border in North Carolina, proved 
to be key factors in the investigation and response. 
The school administrative staff responded immediately to 
DHEC recommendations and began a more intense and vigorous 
cleaning schedule throughout the school. Teachers and other 
staff began observing students washing their hands and ensured 
that soap and other supplies were readily available. Staff and 
children with diarrhea were excluded from school. A parent letter 
was sent out along with a package of information containing 
notification about the outbreak, disease facts, the importance of 
hand washing, and the school exclusion guidelines. Parents were 
instructed to take the letter with them to their child's physician. 
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Changes in the SC 2005 
List of Reportable Conditions and Why Disease 
Reporting is Important!
DIXIE ROBERTS, MPH, RN
By the authority of South Carolina Statute # 44-20-10 and 
Regulation # 61-20, DHEC designates those conditions that shall 
be reported by health care providers and laboratories. Each year 
in January, DHEC updates the List of Reportable Conditions. The 
revised list is published in the Epi-Notes Newsletter and made 
available on the DHEC web site.
In comparison to the many changes in  last year's list, the 
2005 List of Reportable Conditions contains only two revisions 
and three additions; no conditions were deleted. Please take 
a few moments to familiarize yourself with the changes and 
review the "How to Report" and "What to Report" sections. Brief 
explanations regarding the changes can be found on pages 4 - 5 
along with  copies of the List on pages 6 -7. Also, be aware that 
several of the District Public Health Offices have had address 
or phone number changes for their Epidemiology / Disease 
Reporting Office, so please discard the 2004 list and refer only to 
the updated information for 2005. Large color posters and new 
disease reporting cards will be available from your local health 
department. You may print or download a copy of the list from 
the Bureau of Disease Control home page on the DHEC Web site 
at www.scdhec.net. Scroll down the "Health Information" column 
and click on "Infectious Diseases."
Conditions that have been added include:
— Creutzfeldt-Jakob Disease (Age < 55)
— Influenza, pediatric death (age < 17) 
— Meningitis, aseptic
Conditions that have been revised:
— Listeriosis - added reference to footnote # 7 to request 
Labs to submit isolate to the DHEC Lab for typing.
— Influenza, positive rapid flu test by #  (changed to report 
by number only)
(Continued on page 4)      (see GOT SHIGELLA? page 2)
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Shigella is transmitted by direct or indirect fecal-oral route. 
Children less than 5 years of age in childcare settings, caregivers 
of young children and people cohabiting in crowded conditions 
have an increased risk for infection. There is also risk of infection for 
travelers to countries with poor sanitation. Few organisms ( 10-100 
organisms) are needed for infection to occur. Other transmission 
modes include ingestion of contaminated food or water, contact 
with contaminated objects, and sexual contact. The incubation 
period for shigellosis infections is 1-7 days, but most commonly 
2 to 4 days. Illness is usually self-limited; lasting an average of 4-7 
days. The severity of illness and the case fatality rate are functions 
of the host and the serotype. The use of antimicrobials shortens the 
duration of illness. In mild cases of illness, the goal of treatment is 
to prevent the spread of organisms. Shigellosis is best diagnosed 
by stool culture. The best way to prevent transmission of shigellosis 
is through thorough and frequent hand washing. (American 
Academy of Pediatrics; 2003: (551-552).
( see ASK EPI - page 3)
The DHEC Epi Team contacted every person who was reported 
to have symptoms. A questionnaire was completed on each patient 
that included critical information such as illness onset date and 
names of any household contacts who were ill. This data helped 
to assess the likelihood of food or waterborne contamination. The 
District Environmental Health Supervisor inspected the school 
cafeteria, bathrooms, and other sites in the school. for potential 
problems. Local newspapers and television stations ran segments 
on the outbreak, with a focus on handwashing as the best method 
of prevention.
Approximately 80 cases of Shigella were identified in the 
outbreak. Stool specimens were analyzed by various labs, 
including DHEC's Bureau of Labs and the State Lab of North 
Carolina. Seven samples were prepared from subcultures for DNA 
fingerprinting. Pulsed field gel electrophoresis ( PFGE) restriction 
fragments were obtained using the Xba I endonuclease enzyme 
and were processed using the Chef Mapper. All seven isolates 
had the same DNA fingerprint pattern SCSSX088. This is related 
to the most common pattern SCSSX053 (associated with a large 
Waccamaw District outbreak) by a one-band difference and 
to pattern SCSSX061 (associated with recent outbreaks in the 
Upstate) by a two-band difference. Pattern SCSSX088 was first 
isolated from an Anderson patient in October 2003. The second 
occurrence was seen in a patient from Greenville in March 2004. 
This outbreak marks the third time this pattern has been detected 
in South Carolina. No environmental source of contamination, 
such as food or water was found in this outbreak. The dates of 
onset among cases suggest a person-to-person transmission, 
which is typical in outbreaks of Shigella. The physician's role in 
early identification, specimen collection, and prompt reporting 
was instrumental in helping DHEC control the outbreak. The fast 
actions of the community demonstrated an incredible spirit of 
willingness and cooperation. This is a fine example of an organized 
and collaborative approach in detecting and responding to an 
infectious disease outbreak. For additional information or to report 
cases of Shigella, please contact your local health district office. 
The list of reportable diseases and contact numbers can be found 
on the Bureau of Disease Control web page at http://www.scdhec.
net/hs/diseasecont/disease.htm.
DISEASE INFORMATION
Shigella is a gram-negative bacilli, causing acute, bacterial 
infection involving primarily the large intestine. Four species, with 
over 40 serotypes have been identified. Clinical manifestations 
most often include watery or loose stools, but can be more severe, 
causing fever, abdominal cramps, tenesmus and mucoid stools 
with the presence or absence of blood.
Ask Epi
Here in the Division of Acute 
Disease Epi, we receive questions 
on a regular basis from providers 
regarding all matter of issues relating 
to infectious diseases, public health 
and epidemiology. We invite our readers 
to submit questions .to AskEpi@sc.dhec.
gov. In our last issue AskEpi discussed the matter 
of False Positive IgM tests. Here we address questions relating to 
BCG and tuberculin skin testing.
Question:  One of my patients, a 25 year old nurse from Thailand, 
was scheduled to receive a routine pre-employment tuberculin 
skin test (TST) at our local hospital. She said she thought she 
should not be skin tested because she had received BCG vaccine 
in her home country years ago and "what was the point of getting 
tested" since she would "always be tuberculin positive because 
of her BCG anyway." She was also worried that an injection of 
tuberculin would be unsafe and could "slough her arm" and 
recalled being told that since she had received BCG she should 
actually never be skin tested again. Finally, she wondered if the 
whole issue of TB testing for her might actually be moot since she 
was protected by her BCG. In my practice, I've had similar questions 
from other foreign-born patients who also have had BCG. What 
approach do you recommend?
Answer  provided by Eric Brenner, MD:  Several issues are raised 
by this interesting question including: (a) the efficacy of BCG 
vaccination; (b) the effect of BCG vaccination on the tuberculin 
(GOT SHIGELLA? cont'd from page 1)
Page 2
(ASK EPI  continued from page 3)
no radiographic abnormalities, and BCG does not produce 
pulmonary disease in immunocompetent persons. In the less 
likely case that either x-ray showed typical "footprints" of TB 
(e.g. calcifications in hilar nodes and/or in the parenchyma, or 
apical scars), these could, for either child, be taken as evidence 
that the TST was a "true positive." In the absence of evidence 
of TB disease, treatment for latent TB infection would be 
recommended for patient 1. In the absence of evidence of TB 
disease or of pulmonary calcifications, it would be reasonable 
not to treat patient 2, though the potential risks and benefits 
of treatment could be discussed with his parents. 
Comment:   These  hypothetical cases demonstrate a general 
approach to thinking through these types of situations. In the case 
of the Thai you described, one should advise her: (a) that it is safe 
for her to be skin tested, (b) that since she received BCG over 20 
years ago that a large TST reaction now would probably indicate 
true infection with M. tuberculosis, (c) that should her TST measure 
≥10 mm the recommendation would be to ignore her history of 
BCG and consider her to be infected with M. tuberculosis , (d) that 
treatment of latent TB infection would also be recommended ó 
especially since in her new job as a nurse she would potentially 
put many patients at risk should she develop TB.(3)  Also, adverse 
reactions to isoniazid, the drug most commonly used to treat 
LTBI, are uncommon in young patients of her age. A negative pre-
employment TST (the most likely outcome) would provide a useful 
baseline against which to evaluate subsequent annual TSTs as are 
required of hospital employees. Finally, it is important to view 
this entire discussion in the context of the current epidemiology 
of TB in the United States (~15,000 cases per year) where over 
50% of new cases are now diagnosed among the foreign-born, 
most or many of whom had previously received BCG (4,5). In 
South Carolina, only 38 (15%) of the 254 cases reported in 2003 
were foreign-born. Nonetheless, as the foreign-born population 
continues to increase, familiarity with issues relating to BCG, 
tuberculin skin testing, and tuberculosis will be increasingly useful 
in clinical practice.
Note: Consultation about TB can be obtained from DHEC's Division 
of Tuberculosis Control (DTBC) at 803-898-0558 or the TB nurse 
in any County Health Departments who can also refer complex 
clinical questions to one of our TB consultants. The DTBC can also 
arrange for a speaker to address issues relating to TB for hospital 
conferences, grand-rounds, etc. 
References and web resources:
1. The Role of BCG Vaccine in the Prevention and Control 
of Tuberculosis in the United States. (Joint statement 
by  Advisory Council for the Elimination of Tuberculosis 
and the USPHS Advisory Committee on Immunization 
Practices). MMWR April 26, 1996 /Vol 45/No. RR-4. 
[Available online at www.cdc.gov/mmwr/preview/
ind96_rr.html and has 80+ references on BCG.]
2. Tuberculin Skin Test Survey in a Pediatric Population 
with High BCG Vaccination Coverage - Botswana, 
1996. MMWR Weekly of September 12, 1997. [Available 
at www.cdc.gov/mmwr/preview/index97.html]
3. Targeted Tuberculin Testing and Treatment of Latent 
Tuberculosis Infection. MMWR June 9, 2000 / Vol 49 / 
No. RR-6. [Available at www.cdc.gov/mmwr/indrr_2000.
html]
4. Recommendations for Prevention and Control of 
Tuberculosis Among Foreign-Born Persons.  MMWR 
September 18, 1998 / Vol. 47 / No. RR-16. [Available at 
www.cdc.gov/mmwr/preview/ind98_rr.html]
5.   Trends in Tuberculosis - United States, 1998-2003. 
MMWR March 19, 2004 / Vol 53 / No. 10. [Available at: 
www.cdc.gov/mmwr/weekcvol.html]
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                            (see  ASK EPI  page 9)
skin test; and (c) the broader question about tuberculosis among 
foreign-born residents of the United States. 
BCG Vaccine Efficacy BCG (Bacillus of Calmette and Guerin) 
vaccines are live vaccines which are descendents from a strain 
of Mycobacterium bovis attenuated in France over 80 years ago. 
Different strains have different biological characteristics including 
growth characteristics, protective efficacy, and ability to produce 
an immune response to tuberculin.(1)  BCG is widely used around 
the world, especially in high-incidence tuberculosis countries 
where coverage and quality of TB control programs is suboptimal. 
Prospective studies performed at different times and places have 
shown efficacy ranging from 0% to 80% in preventing adult-type 
infectious pulmonary tuberculosis. Retrospective case control 
studies have shown efficacy of the order of 40-80% in preventing 
miliary TB and TB meningitis in young children.(1)  This justifies 
use of BCG in countries where these serious complications of 
childhood TB are common though the benefits are felt to be 
"humanitarian" rather than "epidemiologic" since children with 
these forms of illness are not infectious. Thus BCG is essentially 
used to prevent a certain proportion of severe and/or fatal cases 
of pediatric TB but not with any realistic expectation that its use 
can lead to a decrease in incidence of the disease. In the United 
States and a number of other low-incidence countries, BCG is used 
either in very limited circumstances or not at all because: (a) its 
efficacy is variable and uncertain; (b) in our setting most cases 
of disease arise from the pool of previously infected persons for 
whom vaccination would be "too late"; (c) use of BCG can interfere 
with interpretation of the tuberculin skin test; and (d) other more 
effective TB control strategies are available: e.g. provision of 
directly observed therapy (DOT) which renders infectious persons 
non-infectious; investigation of contacts and treatment of latent 
TB infection (LTBI) to prevent disease, and programs to control 
transmission of TB in institutional settings. Certainly in the practice 
setting, one should never assume that a patient's history of prior 
BCG means the patient cannot develop TB in the future or does not 
have TB right now. Indeed every year in the world many hundreds 
of thousands in Asia, Africa and other high-risk areas develop TB 
although they had received BCG as children. 
Effect of BCG on the tuberculin skin test: The effect of BCG on 
subsequent TSTs is variable, and indeed much of the problem lies 
there. Some persons have large (e.g. ≥ 15 mm) tuberculin reactions 
as a result of BCG, most have smaller reactions (e.g. 5 - 12 mm), 
while yet others are found not to react to tuberculin at all. Thus, 
in France, where every child entering school is given BCG, and all 
children (~700,000 per year) are given a TST several weeks after 
vaccination. Most will show at least some reaction to tuberculin, 
but those that do not are given a second dose of BCG. Though this 
approach is very different than that practiced in the United States, 
one can conclude from it: (a) that it is certainly both common and 
safe to apply a TST to BCG vaccinees, and  (b) that not everyone 
who has received BCG then "converts" their skin test. Further, 
even in vaccinees who do respond to tuberculin after BCG, such 
reactivity tends to wane with the passage of time and is not likely 
to last more than 10 years after vaccination in the absence of 
prior or subsequent infection with Mycobacterium tuberculosis, 
though ongoing periodic skin testing may also prolong reactivity 
in vaccinated persons. An interesting experience was reported by 
the Centers for Disease Control in a study conducted in Botswana 
in a population with high BCG coverage.(2)  There it was found that 
TST induration ≥ 10 mm could most commonly be attributed to TB 
infection and not to previous BCG vaccination. For example, it was 
found that 617 of 783 children studied had zero reactivity after a 
TST which indicated that BCG did not result in TST induration in 
most children. On the other hand, children with reported exposure 
to a case of TB in the household were at much greater risk of having 
reactions ≥ 10 mm. This reinforces the same conclusions drawn 
above from the French experience.
Illustrative Examples from Practice
Patient 1:  An apparently healthy 15 year old child receives a TST as 
part of a general health screening on arrival in the United States 
from a Sudanese refugee camp where he has spent the last four 
years. His skin test reaction measures 11 mm of induration.  He 
has had a scar, consistent with prior BCG, on his right deltoid 
for as long as he can remember. 
Patient 2:  Another apparently healthy 15 year old is seen the 
same day and receives a TST prior to spending July in a private 
summer camp. He also has an 11 mm reaction measured at 48 
hours. This child is from London and lives with his parents in 
Buckingham Palace. He received BCG at age 13 (typical for BCG 
administration in England) and there are no reports of cases of 
TB in the palace or in the Royal Family.
Discussion:  Given their histories, it would be reasonable to take 
different approaches to the two children even though they are 
the same age and had identical reactions to tuberculin. Though 
it is not possible to be 100% certain, it is likely that patient 1 has 
a "true positive" TST, and that patient 2 has a "false positive" due 
to BCG. Patient 1 has lived in a high-TB-incidence environment 
for several years and received vaccine about 15 years ago. It is 
more plausible to attribute his TST result to infection with M. 
tuberculosis than to BCG. On the other hand, patient 2 comes 
from a very low-TB-incidence population and received BCG only 
two years ago so that it is plausible and reasonable to assume 
that his TST is a result of BCG.  It would be prudent to obtain a 
chest x-ray for each child. Both will probably be normal since 
most asymptomatic persons with latent TB infection have 
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Lena Bretous, MD, MPH - Medical Epidemiologist. 
Dr. Bretous obtained her medical degree from Jeffereson 
Medical College in Philadelphia and a Master of Public Health from 
the University of South Carolina. She has an undergraduate degree 
in architecture from Columbia University. She received medical 
specialty training in Preventive Medicine from  USC School of 
Medicine. In addition to her regular duties as a Medical Consultant 
with the Division of Acute Disease Epidemiology, Dr. Bretous is the 
coordinator for West Nile virus and Influenza surveillance.
Wayne Duffus, MD, PhD - Director of HIV and STD Medicine. 
Originally from Kingston, Jamaica, Dr. Duffus graduated 
from the Albert Einstein College of Medicine in Bronx, NY and 
completed residency training in Internal Medicine at the Columbia 
Presbyterian Medical Center in New York City and fellowship 
training in Infectious Diseases at Emory University School of 
Medicine in Atlanta, GA. Most recently her worked as an Epidemic 
Intelligence Service Officer for CDC. Dr. Duffus is on the faculty 
as Clinical Assistant Professor at USC Department of Medicine, 
Division of Infectious Diseases where he sees HIV-AIDS patients in 
the Ryan White Clinic. His duties at DHEC are primarily to conduct 
research in HIV-AIDS and STD, and serve as medical consultant for 
HIV, STD, and hepatitis. He will also provide medical consultation 
to the AIDS Drug Assistance Program and Ryan White Consortia.
G.. T. (Tom) Fabian, MD, MPH - Medical Director, Bioterrorism 
Surveillance and Response Program. 
Dr. Fabian received his medical degree from the Medical 
University of South Carolina and a Master of Public Health from 
the Unversity of Texas Health Science Center at Houston. He has 
a BS in physics from Clemson University and is board certified 
by the American Board Of Preventive Medicine. In 1996, he 
retired as a Colonel from the United States Air Force, and his last 
appointment was Hospital Commander at Shaw A.F.B. Prior to 
joining the Division of Acute Disease Epidemiology, he was the 
District Health Director for the Upper Savannah Public Health 
District from 1997 to 2003. Dr. Fabian provides medical direction 
for the BT Surveillance & Program including the National BT 
Hospital Preparedness Program and the Strategic National 
Stockpile. He also provides oversight of the development of the 
District Mass Casualty Plans and serves as a medical consultant 
in communicable disease epidemiology.
Shirley Jankelevich, MD -  Medical Epidemiologist. 
Dr. Jankelevich earned a BA from Queens College, CUNY 
and completed additional coursework in Biochemistry at Duke 
University and received her medical degree from the Albert 
Einstein College of Medicine, Bronx, N.Y. She completed an 
Internship and Residency in Pediatrics at Yale-New Haven 
Hospital, Department of Pediatrics, Yale University School of 
Medicine and a Postdoctoral Fellowship in Pediatric Infectious 
Diseases, Department of Pediatrics, Yale University School of 
Medicine, New Haven, CT. Dr. Jankelevich is Board Certified in 
both General Pediatrics and in Pediatric Infectious Diseases by 
the American Board of Pediatrics. From  March 2000, she was a 
Medical Officer in the Pediatric Medicine Branch, Therapeutics 
Research Program, Division of AIDS, NIAID at the National Institutes 
of Health. Concurrently, beginning  January 2003, she was an 
Assistant Professor of Pediatrics, Uniformed Services University 
of the Health Sciences, Bethesda, MD. In addition, to her duties 
as a Medical Epidemiolgist with the Division of Acute Disease 
Epidemiology, she will serve as the Medical Consultant for the 
Immunization Division. 
Julie Schlegel, MSPH -  Foodborne Epidemiologist. 
Julie earned a Master of Science and Healthcare Planning 
from Florida State University. Prior to coming to DHEC, she was 
an Epidemiologist with the state of Maine. Julie's position as 
Foodborne Epidemiologist is new with the Division of Acute 
Disease Epidemiology. She coordinates surveillance and response 
for enteric diseases.
Mary Anne Wenck, DVM, MPH - Epidemic Intelligence Service 
(EIS) Officer. 
Dr. Wenck earned her verterinary medicine degree from the 
University of Tennessee and a Master of Public Health degree 
from the University of South Carolina. Her bachelor's degree is in 
biology from Warren Wilson College. She has 11 years experience 
in veterinary practice in Spartanburg, Aiken, and Barnwell. The EIS 
is a CDC training program in field epidemiology. Dr. Wenck has 
joined us to learn about public health in S.C., serve as a liaison 
to CDC, and work as a Medical Epidemiologist in the Division of 
Acute Disease Epi.
Claire Youngblood, MA - Data Manager, Carolina Health 
Electronic Surveillance System (CHESS). 
Claire obtained a BA from Wofford College and a Master of 
Arts in Sociology from the University of South Carolina. Prior to 
joining DHEC, she was a Research Analyst/Statistician at the S.C. 
Department of Alcohol and Other Drug. She also has 11 years 
experience as an Adjunct Professor of Sociology. Claire helps 
maintain data quality in CHESS and assists the Epidemiology staff 
in retrieving and interpreting data.
Meet our New Staff in the Bureau of Disease Control
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Change in Rapid Influenza Test Surveillance 
Lena Bretous, MD, MPH 
 Medical Epidemiologist
This influenza season, each lab and clinical practice should 
report to DHEC the total number of positive influenza rapid 
antigen test each week.  These should be reported for  the lab or 
practice and county where the test is performed and the type of 
influenza (A, B or A/B) that the test detects. This is a change from 
the 2004 influenza rapid test reporting requirements that required 
personal identifying information on each case. This change will 
simplify reporting and improve the timeliness of reporting of 
positive rapid tests.  The positive rapid influenza test results by 
county will be used to monitor flu activity and distribution in 
the state, along with the two other components of the influenza 
surveillance system: laboratory culture of isolates, and the 
statewide sentinel physicians who report rates of influenza-like 
illness in their practice. One may still use 1129 disease report cards 
to report summary numbers of positive rapid tests and virus type 
detected OR use a weekly summary worksheet provided by your 
local health department and fax or email the summary information 
on a weekly basis. 
Please note, positive rapid antigen test by summary 
number does not replace the mandatory reporting of positive 
influenza viral cultures, by name with other personally 
identified information on 1129 cards to DHEC. All other diseases 
on the list continue to require complete demographic information. 
Please remember that influenza surveillance information, updated 
weekly, may be found on the DHEC web site at http://www.scdhec.
net/hs/diseasecont/acuteepi/flu.htm
Pediatric Influenza-related Deaths Surveillance
Lena Bretous, MD, MPH
Medical Epidemiologist
Beginning in 2005, Pediatric influenza-related deaths of 
individuals  up to and including 17 years of age, will be a 
nationally notifiable disease, therefore DHEC is adding this to the 
List of Reportable Diseases. The Council for State and Territorial 
Epidemiologists (CSTE) and the CDC recently made Pediatric 
Influenza-related deaths reportable. Physicians are to report such 
deaths to their local health department. Information required 
includes, but is not limited to: a positive rapid influenza test or 
viral isolate culture, clinical history including complications during 
the acute illness, co-morbid medical conditions that preceded the 
illness, site of medical care (inpatient or outpatient), and history of 
current influenza vaccine status. Physicians should report cases to 
the local health department Disease Surveillance and Response 
Coordinator. 
Surveillance of Aseptic Meningitis 
Shirley Jankelevich, MD
Medical Epidemiologist
Aseptic meningitis has been  added to the SC DHEC List of 
Reportable Conditions in 2005. Surveillance data for aseptic 
meningitis will allow DHEC to monitor changes in trends, 
identify causes of severe cases, and allow interventions during 
outbreaks.
Although most cases of aseptic meningitis are caused by 
enteroviruses, other viruses, partially treated bacterial meningitis, 
fungi, rickettsiae, protozoans, helminthes, spirochetes, and 
a wide variety of noninfectious diseases and conditions and 
medications can also present as aseptic meningitis. For the 
purposes of surveillance in S.C., aseptic meningitis is defined as 
inflammation of the meninges associated with fever, meningeal 
signs and symptoms, CSF pleocytosis with sterile bacterial and 
fungal CSF cultures. 
Viral culture isolates from CSF and other appropriate clinical 
materials should be sent to DHEC Bureau of Laboratories for 
virus identification only during an outbreak of aseptic meningitis. 
DHEC epidemiologists will consult with laboratories to define 
the number of specimens to submit for virus identification in an 
outbreak. 
Revised Listeriosis Reporting Requirement
Julie Schlegel, MSPH
Foodborne Epidemiologist
Listeriosis will be designated as one of the diseases for which 
clinical isolates and serology should be submitted to the DHEC 
Public Health Laboratory for confirmatory testing, serotyping, 
or serogrouping. This enhanced surveillance will aid in the 
identification of clusters and outbreaks of Listeriosis. 
Bureau of Disease Control
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Surveillance for Creutzfeldt-Jakob Disease (CJD) 
will begin in SC in 2005 
Shirley Jankelevich, MD, Medical Epidemiologist
Because of a concern that BSE or variant CJD may occur in the 
US if there are violations of FDA regulations, surveillance for CJD in 
individuals 55 years or younger will be initiated in South Carolina in 
2005. Information on CJD surveillance and laboratory testing may 
be found at  http://www.cjdsurveillance.com. General information 
on CJD may be found on the CDC web site at http://www.cdc.
gov/ncidod/diseases/cjd/cjd.htm.
CJD belongs to a large family of human and animal diseases 
called the transmissible spongiform encephalopathies (TSEs). They 
are named after the characteristic spongiform degeneration of 
infected brains, which become filled with holes until they resemble 
sponges under a microscope. CJD and other TSEs are thought 
to be caused by accumulation of an abnormal form of a cellular 
brain protein called prion protein. Accumulation of the abnormal 
prions in the brain results in severe neurodegenerative disease 
and death. Abnormal prions can form in the brain de novo due 
to mutations in the gene that encodes prion protein resulting in 
familial CJD. Transmission of abnormal proteins to humans may 
occur via the ingestion of meat from cows with bovine spongiform 
encephalopathy (BSE or mad cow disease) and may result in a form 
of CJD called variant CJD (vCJD). 
There are four major forms of human TSEs and each has 
certain distinct clinical and diagnostic features. These are classic, 
variant, iatrogenic, hereditary CJD (Table 1.)  The incubation 
period is unknown but is probably years to decades depending 
on the form of CJD. Table 1 shows the some of the distinguishing 
features and epidemiology of these different forms of CJD. It is 
important to remember that CJD may have symptoms similar to 
other progressive neurological disorders such as Alzheimer's or 
Huntington's disease but can only be distinguished from them 
by identification of the unique histologic changes in brain tissue 
caused by abnormal prions. 
Since 1997, strict regulations by the FDA have been in place 
to help to prevent BSE-infected cattle from entering the US 
food chain. To date, one BSE-infected cow in Washington State 
(imported from Canada) in 2003 and one case of vCJD in a British 
citizen residing in Florida, believed to be transmitted from BSE-
infected beef have been identified in the US.
Table 1:  Forms of Creutzfeld-Jakob Disease
(1) As determined by The National Prion Disease Pathology Surveillance Center 
of Neuropathology of Case Western Reserve University for the period of 




Age at death 
(median)




Number of definite & 
probable cases in US 
(examination of 1511 
suspected cases) (1)
Number of definite & 
probable cases in UK resulting 
in death (examination of 1913 
suspected cases) (2)
CLASSIC CJD
Early neurological signs; 
very rapid progression 
(dementia, myoclonus)
68 UNKNOWN 4-5 MONTHS 753 756
VARIANT CJD
Delayed neurological 
signs (initially have 
behavioral, psychiatric 
signs, then dementia)
28 BSE-INFECTED CATTLE 13-14 
MONTHS







grafts, human dural 
grafts; human-
derived growth 




8-40 MONTHS 5 130
FAMILIAL 
CJD Dementia, myoclonus Genetic mutation ~15 MONTHS 46 42
Changes in the SC 2005 List of Reportable Conditions 
(2) As determined by the National CJD surveillance unit at the Western General 
Hospital in Edinburgh, Scotland for the period of 1990-2004 (this number 
represents a subset of CJD cases in the United Kingdom)
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Change in Rapid Influenza Test Surveillance 
Lena Bretous, MD, MPH 
 Medical Epidemiologist
This influenza season, each lab and clinical practice should 
report to DHEC the total number of positive influenza rapid 
antigen test each week.  These should be reported for  the lab or 
practice and county where the test is performed and the type of 
influenza (A, B or A/B) that the test detects. This is a change from 
the 2004 influenza rapid test reporting requirements that required 
personal identifying information on each case. This change will 
simplify reporting and improve the timeliness of reporting of 
positive rapid tests.  The positive rapid influenza test results by 
county will be used to monitor flu activity and distribution in 
the state, along with the two other components of the influenza 
surveillance system: laboratory culture of isolates, and the 
statewide sentinel physicians who report rates of influenza-like 
illness in their practice. One may still use 1129 disease report cards 
to report summary numbers of positive rapid tests and virus type 
detected OR use a weekly summary worksheet provided by your 
local health department and fax or email the summary information 
on a weekly basis. 
Please note, positive rapid antigen test by summary 
number does not replace the mandatory reporting of positive 
influenza viral cultures, by name with other personally 
identified information on 1129 cards to DHEC. All other diseases 
on the list continue to require complete demographic information. 
Please remember that influenza surveillance information, updated 
weekly, may be found on the DHEC web site at http://www.scdhec.
net/hs/diseasecont/acuteepi/flu.htm
Pediatric Influenza-related Deaths Surveillance
Lena Bretous, MD, MPH
Medical Epidemiologist
Beginning in 2005, Pediatric influenza-related deaths of 
individuals  up to and including 17 years of age, will be a 
nationally notifiable disease, therefore DHEC is adding this to the 
List of Reportable Diseases. The Council for State and Territorial 
Epidemiologists (CSTE) and the CDC recently made Pediatric 
Influenza-related deaths reportable. Physicians are to report such 
deaths to their local health department. Information required 
includes, but is not limited to: a positive rapid influenza test or 
viral isolate culture, clinical history including complications during 
the acute illness, co-morbid medical conditions that preceded the 
illness, site of medical care (inpatient or outpatient), and history of 
current influenza vaccine status. Physicians should report cases to 
the local health department Disease Surveillance and Response 
Coordinator. 
Surveillance of Aseptic Meningitis 
Shirley Jankelevich, MD
Medical Epidemiologist
Aseptic meningitis has been  added to the SC DHEC List of 
Reportable Conditions in 2005. Surveillance data for aseptic 
meningitis will allow DHEC to monitor changes in trends, 
identify causes of severe cases, and allow interventions during 
outbreaks.
Although most cases of aseptic meningitis are caused by 
enteroviruses, other viruses, partially treated bacterial meningitis, 
fungi, rickettsiae, protozoans, helminthes, spirochetes, and 
a wide variety of noninfectious diseases and conditions and 
medications can also present as aseptic meningitis. For the 
purposes of surveillance in S.C., aseptic meningitis is defined as 
inflammation of the meninges associated with fever, meningeal 
signs and symptoms, CSF pleocytosis with sterile bacterial and 
fungal CSF cultures. 
Viral culture isolates from CSF and other appropriate clinical 
materials should be sent to DHEC Bureau of Laboratories for 
virus identification only during an outbreak of aseptic meningitis. 
DHEC epidemiologists will consult with laboratories to define 
the number of specimens to submit for virus identification in an 
outbreak. 
Revised Listeriosis Reporting Requirement
Julie Schlegel, MSPH
Foodborne Epidemiologist
Listeriosis will be designated as one of the diseases for which 
clinical isolates and serology should be submitted to the DHEC 
Public Health Laboratory for confirmatory testing, serotyping, 
or serogrouping. This enhanced surveillance will aid in the 
identification of clusters and outbreaks of Listeriosis. 
Bureau of Disease Control
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Surveillance for Creutzfeldt-Jakob Disease (CJD) 
will begin in SC in 2005 
Shirley Jankelevich, MD, Medical Epidemiologist
Because of a concern that BSE or variant CJD may occur in the 
US if there are violations of FDA regulations, surveillance for CJD in 
individuals 55 years or younger will be initiated in South Carolina in 
2005. Information on CJD surveillance and laboratory testing may 
be found at  http://www.cjdsurveillance.com. General information 
on CJD may be found on the CDC web site at http://www.cdc.
gov/ncidod/diseases/cjd/cjd.htm.
CJD belongs to a large family of human and animal diseases 
called the transmissible spongiform encephalopathies (TSEs). They 
are named after the characteristic spongiform degeneration of 
infected brains, which become filled with holes until they resemble 
sponges under a microscope. CJD and other TSEs are thought 
to be caused by accumulation of an abnormal form of a cellular 
brain protein called prion protein. Accumulation of the abnormal 
prions in the brain results in severe neurodegenerative disease 
and death. Abnormal prions can form in the brain de novo due 
to mutations in the gene that encodes prion protein resulting in 
familial CJD. Transmission of abnormal proteins to humans may 
occur via the ingestion of meat from cows with bovine spongiform 
encephalopathy (BSE or mad cow disease) and may result in a form 
of CJD called variant CJD (vCJD). 
There are four major forms of human TSEs and each has 
certain distinct clinical and diagnostic features. These are classic, 
variant, iatrogenic, hereditary CJD (Table 1.)  The incubation 
period is unknown but is probably years to decades depending 
on the form of CJD. Table 1 shows the some of the distinguishing 
features and epidemiology of these different forms of CJD. It is 
important to remember that CJD may have symptoms similar to 
other progressive neurological disorders such as Alzheimer's or 
Huntington's disease but can only be distinguished from them 
by identification of the unique histologic changes in brain tissue 
caused by abnormal prions. 
Since 1997, strict regulations by the FDA have been in place 
to help to prevent BSE-infected cattle from entering the US 
food chain. To date, one BSE-infected cow in Washington State 
(imported from Canada) in 2003 and one case of vCJD in a British 
citizen residing in Florida, believed to be transmitted from BSE-
infected beef have been identified in the US.
Table 1:  Forms of Creutzfeld-Jakob Disease
(1) As determined by The National Prion Disease Pathology Surveillance Center 
of Neuropathology of Case Western Reserve University for the period of 




Age at death 
(median)




Number of definite & 
probable cases in US 
(examination of 1511 
suspected cases) (1)
Number of definite & 
probable cases in UK resulting 
in death (examination of 1913 
suspected cases) (2)
CLASSIC CJD
Early neurological signs; 
very rapid progression 
(dementia, myoclonus)
68 UNKNOWN 4-5 MONTHS 753 756
VARIANT CJD
Delayed neurological 
signs (initially have 
behavioral, psychiatric 
signs, then dementia)
28 BSE-INFECTED CATTLE 13-14 
MONTHS







grafts, human dural 
grafts; human-
derived growth 




8-40 MONTHS 5 130
FAMILIAL 
CJD Dementia, myoclonus Genetic mutation ~15 MONTHS 46 42
Changes in the SC 2005 List of Reportable Conditions 
(2) As determined by the National CJD surveillance unit at the Western General 
Hospital in Edinburgh, Scotland for the period of 1990-2004 (this number 
represents a subset of CJD cases in the United Kingdom)
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(ASK EPI - continued from page 2)
                            (see  ASK EPI  page 9)
skin test; and (c) the broader question about tuberculosis among 
foreign-born residents of the United States. 
BCG Vaccine Efficacy BCG (Bacillus of Calmette and Guerin) 
vaccines are live vaccines which are descendents from a strain 
of Mycobacterium bovis attenuated in France over 80 years ago. 
Different strains have different biological characteristics including 
growth characteristics, protective efficacy, and ability to produce 
an immune response to tuberculin.(1)  BCG is widely used around 
the world, especially in high-incidence tuberculosis countries 
where coverage and quality of TB control programs is suboptimal. 
Prospective studies performed at different times and places have 
shown efficacy ranging from 0% to 80% in preventing adult-type 
infectious pulmonary tuberculosis. Retrospective case control 
studies have shown efficacy of the order of 40-80% in preventing 
miliary TB and TB meningitis in young children.(1)  This justifies 
use of BCG in countries where these serious complications of 
childhood TB are common though the benefits are felt to be 
"humanitarian" rather than "epidemiologic" since children with 
these forms of illness are not infectious. Thus BCG is essentially 
used to prevent a certain proportion of severe and/or fatal cases 
of pediatric TB but not with any realistic expectation that its use 
can lead to a decrease in incidence of the disease. In the United 
States and a number of other low-incidence countries, BCG is used 
either in very limited circumstances or not at all because: (a) its 
efficacy is variable and uncertain; (b) in our setting most cases 
of disease arise from the pool of previously infected persons for 
whom vaccination would be "too late"; (c) use of BCG can interfere 
with interpretation of the tuberculin skin test; and (d) other more 
effective TB control strategies are available: e.g. provision of 
directly observed therapy (DOT) which renders infectious persons 
non-infectious; investigation of contacts and treatment of latent 
TB infection (LTBI) to prevent disease, and programs to control 
transmission of TB in institutional settings. Certainly in the practice 
setting, one should never assume that a patient's history of prior 
BCG means the patient cannot develop TB in the future or does not 
have TB right now. Indeed every year in the world many hundreds 
of thousands in Asia, Africa and other high-risk areas develop TB 
although they had received BCG as children. 
Effect of BCG on the tuberculin skin test: The effect of BCG on 
subsequent TSTs is variable, and indeed much of the problem lies 
there. Some persons have large (e.g. ≥ 15 mm) tuberculin reactions 
as a result of BCG, most have smaller reactions (e.g. 5 - 12 mm), 
while yet others are found not to react to tuberculin at all. Thus, 
in France, where every child entering school is given BCG, and all 
children (~700,000 per year) are given a TST several weeks after 
vaccination. Most will show at least some reaction to tuberculin, 
but those that do not are given a second dose of BCG. Though this 
approach is very different than that practiced in the United States, 
one can conclude from it: (a) that it is certainly both common and 
safe to apply a TST to BCG vaccinees, and  (b) that not everyone 
who has received BCG then "converts" their skin test. Further, 
even in vaccinees who do respond to tuberculin after BCG, such 
reactivity tends to wane with the passage of time and is not likely 
to last more than 10 years after vaccination in the absence of 
prior or subsequent infection with Mycobacterium tuberculosis, 
though ongoing periodic skin testing may also prolong reactivity 
in vaccinated persons. An interesting experience was reported by 
the Centers for Disease Control in a study conducted in Botswana 
in a population with high BCG coverage.(2)  There it was found that 
TST induration ≥ 10 mm could most commonly be attributed to TB 
infection and not to previous BCG vaccination. For example, it was 
found that 617 of 783 children studied had zero reactivity after a 
TST which indicated that BCG did not result in TST induration in 
most children. On the other hand, children with reported exposure 
to a case of TB in the household were at much greater risk of having 
reactions ≥ 10 mm. This reinforces the same conclusions drawn 
above from the French experience.
Illustrative Examples from Practice
Patient 1:  An apparently healthy 15 year old child receives a TST as 
part of a general health screening on arrival in the United States 
from a Sudanese refugee camp where he has spent the last four 
years. His skin test reaction measures 11 mm of induration.  He 
has had a scar, consistent with prior BCG, on his right deltoid 
for as long as he can remember. 
Patient 2:  Another apparently healthy 15 year old is seen the 
same day and receives a TST prior to spending July in a private 
summer camp. He also has an 11 mm reaction measured at 48 
hours. This child is from London and lives with his parents in 
Buckingham Palace. He received BCG at age 13 (typical for BCG 
administration in England) and there are no reports of cases of 
TB in the palace or in the Royal Family.
Discussion:  Given their histories, it would be reasonable to take 
different approaches to the two children even though they are 
the same age and had identical reactions to tuberculin. Though 
it is not possible to be 100% certain, it is likely that patient 1 has 
a "true positive" TST, and that patient 2 has a "false positive" due 
to BCG. Patient 1 has lived in a high-TB-incidence environment 
for several years and received vaccine about 15 years ago. It is 
more plausible to attribute his TST result to infection with M. 
tuberculosis than to BCG. On the other hand, patient 2 comes 
from a very low-TB-incidence population and received BCG only 
two years ago so that it is plausible and reasonable to assume 
that his TST is a result of BCG.  It would be prudent to obtain a 
chest x-ray for each child. Both will probably be normal since 
most asymptomatic persons with latent TB infection have 
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Lena Bretous, MD, MPH - Medical Epidemiologist. 
Dr. Bretous obtained her medical degree from Jeffereson 
Medical College in Philadelphia and a Master of Public Health from 
the University of South Carolina. She has an undergraduate degree 
in architecture from Columbia University. She received medical 
specialty training in Preventive Medicine from  USC School of 
Medicine. In addition to her regular duties as a Medical Consultant 
with the Division of Acute Disease Epidemiology, Dr. Bretous is the 
coordinator for West Nile virus and Influenza surveillance.
Wayne Duffus, MD, PhD - Director of HIV and STD Medicine. 
Originally from Kingston, Jamaica, Dr. Duffus graduated 
from the Albert Einstein College of Medicine in Bronx, NY and 
completed residency training in Internal Medicine at the Columbia 
Presbyterian Medical Center in New York City and fellowship 
training in Infectious Diseases at Emory University School of 
Medicine in Atlanta, GA. Most recently her worked as an Epidemic 
Intelligence Service Officer for CDC. Dr. Duffus is on the faculty 
as Clinical Assistant Professor at USC Department of Medicine, 
Division of Infectious Diseases where he sees HIV-AIDS patients in 
the Ryan White Clinic. His duties at DHEC are primarily to conduct 
research in HIV-AIDS and STD, and serve as medical consultant for 
HIV, STD, and hepatitis. He will also provide medical consultation 
to the AIDS Drug Assistance Program and Ryan White Consortia.
G.. T. (Tom) Fabian, MD, MPH - Medical Director, Bioterrorism 
Surveillance and Response Program. 
Dr. Fabian received his medical degree from the Medical 
University of South Carolina and a Master of Public Health from 
the Unversity of Texas Health Science Center at Houston. He has 
a BS in physics from Clemson University and is board certified 
by the American Board Of Preventive Medicine. In 1996, he 
retired as a Colonel from the United States Air Force, and his last 
appointment was Hospital Commander at Shaw A.F.B. Prior to 
joining the Division of Acute Disease Epidemiology, he was the 
District Health Director for the Upper Savannah Public Health 
District from 1997 to 2003. Dr. Fabian provides medical direction 
for the BT Surveillance & Program including the National BT 
Hospital Preparedness Program and the Strategic National 
Stockpile. He also provides oversight of the development of the 
District Mass Casualty Plans and serves as a medical consultant 
in communicable disease epidemiology.
Shirley Jankelevich, MD -  Medical Epidemiologist. 
Dr. Jankelevich earned a BA from Queens College, CUNY 
and completed additional coursework in Biochemistry at Duke 
University and received her medical degree from the Albert 
Einstein College of Medicine, Bronx, N.Y. She completed an 
Internship and Residency in Pediatrics at Yale-New Haven 
Hospital, Department of Pediatrics, Yale University School of 
Medicine and a Postdoctoral Fellowship in Pediatric Infectious 
Diseases, Department of Pediatrics, Yale University School of 
Medicine, New Haven, CT. Dr. Jankelevich is Board Certified in 
both General Pediatrics and in Pediatric Infectious Diseases by 
the American Board of Pediatrics. From  March 2000, she was a 
Medical Officer in the Pediatric Medicine Branch, Therapeutics 
Research Program, Division of AIDS, NIAID at the National Institutes 
of Health. Concurrently, beginning  January 2003, she was an 
Assistant Professor of Pediatrics, Uniformed Services University 
of the Health Sciences, Bethesda, MD. In addition, to her duties 
as a Medical Epidemiolgist with the Division of Acute Disease 
Epidemiology, she will serve as the Medical Consultant for the 
Immunization Division. 
Julie Schlegel, MSPH -  Foodborne Epidemiologist. 
Julie earned a Master of Science and Healthcare Planning 
from Florida State University. Prior to coming to DHEC, she was 
an Epidemiologist with the state of Maine. Julie's position as 
Foodborne Epidemiologist is new with the Division of Acute 
Disease Epidemiology. She coordinates surveillance and response 
for enteric diseases.
Mary Anne Wenck, DVM, MPH - Epidemic Intelligence Service 
(EIS) Officer. 
Dr. Wenck earned her verterinary medicine degree from the 
University of Tennessee and a Master of Public Health degree 
from the University of South Carolina. Her bachelor's degree is in 
biology from Warren Wilson College. She has 11 years experience 
in veterinary practice in Spartanburg, Aiken, and Barnwell. The EIS 
is a CDC training program in field epidemiology. Dr. Wenck has 
joined us to learn about public health in S.C., serve as a liaison 
to CDC, and work as a Medical Epidemiologist in the Division of 
Acute Disease Epi.
Claire Youngblood, MA - Data Manager, Carolina Health 
Electronic Surveillance System (CHESS). 
Claire obtained a BA from Wofford College and a Master of 
Arts in Sociology from the University of South Carolina. Prior to 
joining DHEC, she was a Research Analyst/Statistician at the S.C. 
Department of Alcohol and Other Drug. She also has 11 years 
experience as an Adjunct Professor of Sociology. Claire helps 
maintain data quality in CHESS and assists the Epidemiology staff 
in retrieving and interpreting data.
Meet our New Staff in the Bureau of Disease Control
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Shigella is transmitted by direct or indirect fecal-oral route. 
Children less than 5 years of age in childcare settings, caregivers 
of young children and people cohabiting in crowded conditions 
have an increased risk for infection. There is also risk of infection for 
travelers to countries with poor sanitation. Few organisms ( 10-100 
organisms) are needed for infection to occur. Other transmission 
modes include ingestion of contaminated food or water, contact 
with contaminated objects, and sexual contact. The incubation 
period for shigellosis infections is 1-7 days, but most commonly 
2 to 4 days. Illness is usually self-limited; lasting an average of 4-7 
days. The severity of illness and the case fatality rate are functions 
of the host and the serotype. The use of antimicrobials shortens the 
duration of illness. In mild cases of illness, the goal of treatment is 
to prevent the spread of organisms. Shigellosis is best diagnosed 
by stool culture. The best way to prevent transmission of shigellosis 
is through thorough and frequent hand washing. (American 
Academy of Pediatrics; 2003: (551-552).
( see ASK EPI - page 3)
The DHEC Epi Team contacted every person who was reported 
to have symptoms. A questionnaire was completed on each patient 
that included critical information such as illness onset date and 
names of any household contacts who were ill. This data helped 
to assess the likelihood of food or waterborne contamination. The 
District Environmental Health Supervisor inspected the school 
cafeteria, bathrooms, and other sites in the school. for potential 
problems. Local newspapers and television stations ran segments 
on the outbreak, with a focus on handwashing as the best method 
of prevention.
Approximately 80 cases of Shigella were identified in the 
outbreak. Stool specimens were analyzed by various labs, 
including DHEC's Bureau of Labs and the State Lab of North 
Carolina. Seven samples were prepared from subcultures for DNA 
fingerprinting. Pulsed field gel electrophoresis ( PFGE) restriction 
fragments were obtained using the Xba I endonuclease enzyme 
and were processed using the Chef Mapper. All seven isolates 
had the same DNA fingerprint pattern SCSSX088. This is related 
to the most common pattern SCSSX053 (associated with a large 
Waccamaw District outbreak) by a one-band difference and 
to pattern SCSSX061 (associated with recent outbreaks in the 
Upstate) by a two-band difference. Pattern SCSSX088 was first 
isolated from an Anderson patient in October 2003. The second 
occurrence was seen in a patient from Greenville in March 2004. 
This outbreak marks the third time this pattern has been detected 
in South Carolina. No environmental source of contamination, 
such as food or water was found in this outbreak. The dates of 
onset among cases suggest a person-to-person transmission, 
which is typical in outbreaks of Shigella. The physician's role in 
early identification, specimen collection, and prompt reporting 
was instrumental in helping DHEC control the outbreak. The fast 
actions of the community demonstrated an incredible spirit of 
willingness and cooperation. This is a fine example of an organized 
and collaborative approach in detecting and responding to an 
infectious disease outbreak. For additional information or to report 
cases of Shigella, please contact your local health district office. 
The list of reportable diseases and contact numbers can be found 
on the Bureau of Disease Control web page at http://www.scdhec.
net/hs/diseasecont/disease.htm.
DISEASE INFORMATION
Shigella is a gram-negative bacilli, causing acute, bacterial 
infection involving primarily the large intestine. Four species, with 
over 40 serotypes have been identified. Clinical manifestations 
most often include watery or loose stools, but can be more severe, 
causing fever, abdominal cramps, tenesmus and mucoid stools 
with the presence or absence of blood.
Ask Epi
Here in the Division of Acute 
Disease Epi, we receive questions 
on a regular basis from providers 
regarding all matter of issues relating 
to infectious diseases, public health 
and epidemiology. We invite our readers 
to submit questions .to AskEpi@sc.dhec.
gov. In our last issue AskEpi discussed the matter 
of False Positive IgM tests. Here we address questions relating to 
BCG and tuberculin skin testing.
Question:  One of my patients, a 25 year old nurse from Thailand, 
was scheduled to receive a routine pre-employment tuberculin 
skin test (TST) at our local hospital. She said she thought she 
should not be skin tested because she had received BCG vaccine 
in her home country years ago and "what was the point of getting 
tested" since she would "always be tuberculin positive because 
of her BCG anyway." She was also worried that an injection of 
tuberculin would be unsafe and could "slough her arm" and 
recalled being told that since she had received BCG she should 
actually never be skin tested again. Finally, she wondered if the 
whole issue of TB testing for her might actually be moot since she 
was protected by her BCG. In my practice, I've had similar questions 
from other foreign-born patients who also have had BCG. What 
approach do you recommend?
Answer  provided by Eric Brenner, MD:  Several issues are raised 
by this interesting question including: (a) the efficacy of BCG 
vaccination; (b) the effect of BCG vaccination on the tuberculin 
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no radiographic abnormalities, and BCG does not produce 
pulmonary disease in immunocompetent persons. In the less 
likely case that either x-ray showed typical "footprints" of TB 
(e.g. calcifications in hilar nodes and/or in the parenchyma, or 
apical scars), these could, for either child, be taken as evidence 
that the TST was a "true positive." In the absence of evidence 
of TB disease, treatment for latent TB infection would be 
recommended for patient 1. In the absence of evidence of TB 
disease or of pulmonary calcifications, it would be reasonable 
not to treat patient 2, though the potential risks and benefits 
of treatment could be discussed with his parents. 
Comment:   These  hypothetical cases demonstrate a general 
approach to thinking through these types of situations. In the case 
of the Thai you described, one should advise her: (a) that it is safe 
for her to be skin tested, (b) that since she received BCG over 20 
years ago that a large TST reaction now would probably indicate 
true infection with M. tuberculosis, (c) that should her TST measure 
≥10 mm the recommendation would be to ignore her history of 
BCG and consider her to be infected with M. tuberculosis , (d) that 
treatment of latent TB infection would also be recommended ó 
especially since in her new job as a nurse she would potentially 
put many patients at risk should she develop TB.(3)  Also, adverse 
reactions to isoniazid, the drug most commonly used to treat 
LTBI, are uncommon in young patients of her age. A negative pre-
employment TST (the most likely outcome) would provide a useful 
baseline against which to evaluate subsequent annual TSTs as are 
required of hospital employees. Finally, it is important to view 
this entire discussion in the context of the current epidemiology 
of TB in the United States (~15,000 cases per year) where over 
50% of new cases are now diagnosed among the foreign-born, 
most or many of whom had previously received BCG (4,5). In 
South Carolina, only 38 (15%) of the 254 cases reported in 2003 
were foreign-born. Nonetheless, as the foreign-born population 
continues to increase, familiarity with issues relating to BCG, 
tuberculin skin testing, and tuberculosis will be increasingly useful 
in clinical practice.
Note: Consultation about TB can be obtained from DHEC's Division 
of Tuberculosis Control (DTBC) at 803-898-0558 or the TB nurse 
in any County Health Departments who can also refer complex 
clinical questions to one of our TB consultants. The DTBC can also 
arrange for a speaker to address issues relating to TB for hospital 
conferences, grand-rounds, etc. 
References and web resources:
1. The Role of BCG Vaccine in the Prevention and Control 
of Tuberculosis in the United States. (Joint statement 
by  Advisory Council for the Elimination of Tuberculosis 
and the USPHS Advisory Committee on Immunization 
Practices). MMWR April 26, 1996 /Vol 45/No. RR-4. 
[Available online at www.cdc.gov/mmwr/preview/
ind96_rr.html and has 80+ references on BCG.]
2. Tuberculin Skin Test Survey in a Pediatric Population 
with High BCG Vaccination Coverage - Botswana, 
1996. MMWR Weekly of September 12, 1997. [Available 
at www.cdc.gov/mmwr/preview/index97.html]
3. Targeted Tuberculin Testing and Treatment of Latent 
Tuberculosis Infection. MMWR June 9, 2000 / Vol 49 / 
No. RR-6. [Available at www.cdc.gov/mmwr/indrr_2000.
html]
4. Recommendations for Prevention and Control of 
Tuberculosis Among Foreign-Born Persons.  MMWR 
September 18, 1998 / Vol. 47 / No. RR-16. [Available at 
www.cdc.gov/mmwr/preview/ind98_rr.html]
5.   Trends in Tuberculosis - United States, 1998-2003. 
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Got Shigella? A Community Responds
 Fran Hall, RN, BSN
Pee Dee District Director, Disease 
Surveillance & Response
Stacy  Holley, RN, BSN
Disease Surveillance & Response Nurse
In early August of 2004, a local school nurse in Marlboro County 
notified the District DHEC Epi Nurse that about half the children in 
a pre-k class had a diarrhea illness, which seemed to be spreading. 
This was a large school of approximately 800 students in grades 
pre-k to eight and was very close to the North Carolina border. An 
epidemiological investigation was initiated immediately, which 
soon confirmed an outbreak of Shigella.
 The main objectives of the investigation were to stop further 
transmission and to identify the causative organism. A Physician's 
Advisory was prepared and faxed to all healthcare providers 
to alert them about the increased number of cases of Shigella. 
Included in the advisory was information on transmission modes, 
symptoms, treatment methods, and ways to report illnesses 
to DHEC. Physicians were also directed to the DHEC web site 
for accessing the 2004-2005 School Exclusion Guidelines to 
assist them in determining when a child could return to school. 
Communication with local physicians and emergency rooms in the 
area, including those across the border in North Carolina, proved 
to be key factors in the investigation and response. 
The school administrative staff responded immediately to 
DHEC recommendations and began a more intense and vigorous 
cleaning schedule throughout the school. Teachers and other 
staff began observing students washing their hands and ensured 
that soap and other supplies were readily available. Staff and 
children with diarrhea were excluded from school. A parent letter 
was sent out along with a package of information containing 
notification about the outbreak, disease facts, the importance of 
hand washing, and the school exclusion guidelines. Parents were 
instructed to take the letter with them to their child's physician. 
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Changes in the SC 2005 
List of Reportable Conditions and Why Disease 
Reporting is Important!
DIXIE ROBERTS, MPH, RN
By the authority of South Carolina Statute # 44-20-10 and 
Regulation # 61-20, DHEC designates those conditions that shall 
be reported by health care providers and laboratories. Each year 
in January, DHEC updates the List of Reportable Conditions. The 
revised list is published in the Epi-Notes Newsletter and made 
available on the DHEC web site.
In comparison to the many changes in  last year's list, the 
2005 List of Reportable Conditions contains only two revisions 
and three additions; no conditions were deleted. Please take 
a few moments to familiarize yourself with the changes and 
review the "How to Report" and "What to Report" sections. Brief 
explanations regarding the changes can be found on pages 4 - 5 
along with  copies of the List on pages 6 -7. Also, be aware that 
several of the District Public Health Offices have had address 
or phone number changes for their Epidemiology / Disease 
Reporting Office, so please discard the 2004 list and refer only to 
the updated information for 2005. Large color posters and new 
disease reporting cards will be available from your local health 
department. You may print or download a copy of the list from 
the Bureau of Disease Control home page on the DHEC Web site 
at www.scdhec.net. Scroll down the "Health Information" column 
and click on "Infectious Diseases."
Conditions that have been added include:
— Creutzfeldt-Jakob Disease (Age < 55)
— Influenza, pediatric death (age < 17) 
— Meningitis, aseptic
Conditions that have been revised:
— Listeriosis - added reference to footnote # 7 to request 
Labs to submit isolate to the DHEC Lab for typing.
— Influenza, positive rapid flu test by #  (changed to report 
by number only)
(Continued on page 4)      (see GOT SHIGELLA? page 2)
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 For immediately reportable conditions, call your health district office 
or 1-888-847-0902. Routine reports may be phoned in to district or 
local health department or mailed on a completed DHEC DISEASE 
REPORTING CARD (DHEC 1129) . District Public Health Office numbers 
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or visit 
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